Palantir's Stock: A Tale of Record Growth and Mounting Scrutiny

Palantir's U.S. commercial revenue soared 137%, but its European expansion faces political and ethical challenges over government contracts, even as defense deals fuel a bullish 2026 outlook.

The data analytics firm Palantir finds itself navigating a complex landscape defined by explosive financial performance and increasing regulatory headwinds. While demand from U.S. commercial clients is fueling unprecedented revenue growth, the company's expansion in Europe faces significant political and ethical challenges, particularly concerning its work with government agencies.

Stellar Financial Performance Meets Lofty Valuation

Operational results from Palantir's most recent quarter reveal a business in hyper-growth mode. Total revenue surged 70% year-over-year to reach $1.41 billion. The most dramatic increase came from its U.S. commercial segment, which expanded by a remarkable 137% to $507 million. Revenue from government contracts also saw substantial growth, rising by 66%.

This financial momentum, however, has translated into an exceptionally rich valuation on the stock market. The shares currently trade at a price-to-sales multiple of approximately 80 and a price-to-earnings ratio exceeding 230. Such metrics leave little room for operational missteps or a slowdown in international demand. Concurrently, company insiders have been capitalizing on the elevated share prices of recent years. Over the past 90 days, executives have sold stock valued at roughly $137.7 million. Institutional investor activity presents a mixed picture: Sovran Advisors increased its stake by 46.2%, while Perpetual Ltd reduced its holdings by nearly 47%.

European Contracts Under the Microscope

In Europe, a wave of political resistance is building. The focus of current debate is a substantial seven-year contract worth £330 million with the UK's National Health Service (NHS) for its data platform. Despite the system's current deployment across 123 hospital trusts, critics are exploring legal avenues and exit clauses to halt its further expansion.

A separate, shorter-term contract with Britain's Financial Conduct Authority (FCA) is also drawing scrutiny. Official concerns center on creating an over-reliance on the U.S. technology provider and the ethical implications of its involvement. This skepticism is largely rooted in Palantir's deep ties to the defense and military sector, a connection recently underscored by management's public statements promoting military applications for its artificial intelligence systems.

Defense Sector Backs a Confident Outlook

Management has issued a highly optimistic forecast for the full fiscal year 2026. They project annual revenue between $7.18 billion and $7.20 billion, representing an anticipated growth rate of about 61%. Adjusted operating income is expected to climb to approximately $4.13 billion.

A central pillar supporting this bullish outlook remains the defense industry. A significant endorsement came from the Pentagon's decision to designate Palantir's Maven AI system as an official standard program, securing long-term, reliable funding for the company. While these stable defense revenues provide a buffer against commercial volatility, they are also likely to continue fueling the ethical debates surrounding the award of civilian public sector contracts in Europe.